Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
Abstract The rapid rise in the prevalence of type 2 diabetes mellitus (T2DM) poses a huge healthcare burden across the world. Although there are several antihyperglycaemic agents (AHAs) available including addition of new drug classes to the treatment algorithm, more than 50% of patients with T2DM d...
Main Authors: | Yuki Fujiwara, Shunsuke Eguchi, Hiroki Murayama, Yuri Takahashi, Mitsutoshi Toda, Kota Imai, Kinsuke Tsuda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Endocrinology, Diabetes & Metabolism |
Subjects: | |
Online Access: | https://doi.org/10.1002/edm2.68 |
Similar Items
-
GLP-1 effects on pancreatic b-cell lines
by: Sinclair, Elaine M.
Published: (2002) -
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01) -
The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
by: Antza C, et al.
Published: (2019-08-01) -
Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01) -
Effect of GLP-1 agonist on osteoblast proliferation and related signaling pathways
by: Jian-Qiang Gao, et al.
Published: (2018-09-01)